血糖控制和静止剂使用对糖尿病-结核病治疗结果的相互作用:一个嵌套的病例控制研究
Xiangrui Meng1, Huiqiu Zheng1, Jian Du2
1Center for Data Science in Health and Medicine, School of Public Health, Inner Mongolia Medical University, Hohhot 010110, China.
概括
优化血糖控制和使用他类药物显著影响肺结核 - 糖尿病并发症 (PTB-DM) 患者的治疗结果. 良好的血糖控制与他类药物的使用相结合,产生了最好的结果,减少了不利的结果.
科学领域:
- 医学研究 医学研究
- 临床流行病学 临床流行病学
- 公共卫生 公共卫生
背景情况:
- 肺结核和糖尿病 (PTB-DM) 伴随性疾病带来了复杂的治疗挑战.
- 了解影响PTB-DM治疗结果的因素对于改善患者护理至关重要.
- 在PTB-DM结果中,血糖控制和他类药物使用之间的相互作用需要进一步研究.
研究的目的:
- 调查血糖控制和他类药物使用对PTB-DM患者治疗结果的相互作用.
- 确定PTB-DM患者的最佳管理策略.
- 量化结合血糖控制和他类药物治疗对不良治疗结果的影响.
主要方法:
- 在一组结核病患者中进行了一项嵌套病例控制研究.
- 病例被定义为治疗结果不利的患者.
- 多变量逻辑回归和安德森的相互作用表被用来分析来自2047名患者的数据.
主要成果:
- 在血糖控制和他类药物使用之间观察到与治疗结果有关的显著相互作用.
- 具有良好的血糖控制和使用他类药物的患者表现出最低的不良结果风险 (OR = 0.394).
- 即使在血糖控制不佳的患者中,他类药物的使用也有益,降低了不良结果的风险.
结论:
- 血糖控制是管理PTB-DM的关键因素.
- 立方体治疗对PTB-DM患者提供了好处,无论他们的血糖控制状况如何.
- 将良好的血糖控制与他类药物的使用相结合,可使PTB-DM患者获得最有利的治疗结果.
相关概念视频
Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
Pulmonary Tuberculosis I
231
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
231
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
635
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
635
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
169
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
169


